Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry to disappoint you, mate, but none of those are OTC stocks... they are forgein-traded stocks ... foreign listed companies from other counties who can only list on OTC in the US as a secondary, non-primary market listing.
As much as I'd love to support you and agree with you here, I can't because the logic and premise is incorrect.
If you believe the Bible's version, it says God created the world and everything in it in 6 days (periods), not 7.
The seventh, he rested. Hence why most western religions "rest" on the Sabbath.
---
Regarding LP lying about TLD ... I disagree. They had actual plans and a placeholder for publishing in the Journal of Immunotherapy of Cancer (https://jitc.bmj.com/content/8/Suppl_3/A471.1 ) to be published in Nov 2020, which was withdrawn prior to this for unknown reasons, which is the cause of speculation as to why.
I do not believe management has intentionally lied to anyone about anything regarding their plans. Rather, situation and information beyond their control have changed the timeline and course of events.
Either way, all breadcrumbs lead to an amazing story of something spectacular about to happen. And I would certainly rather be here holding shares that miss out or be short.
That's a bit like Christians who believe that God created the world in six 24-hr days. Not everything in life is literal; Many things are figurative / allegorical / symbolic.
Awesome, Lykiri! Thanks ... I was pretty sure I wasn't imagining that 40k shareholders number ... thanks for looking this up!!!
Thanks for the confirmation ... not sure where the 40k is coming from then ... really thought I read this though (maybe I'm confusing that number with a different investment I had last year or something, thought I couldn't have sworn it was NWBO) Well, wishful thinking then I guess ...
Didn't NWBO have around 40k shareholders beginning of the year? I notice that as of March, there are only 15k reported shareholders (OTC Marktets info) ... that is HUGE consolidation within a smaller group of shareholders .... I agree that someone(s)' building up major stakes in NWBO ....
If I remember correctly, Matt had been suffering from GBM already for quite some time and had been through other therapies, which didn't work. He was quite progressed by the time he was able to get access to DCVax ... I would not say that this is the standard patient type to which the P3 trial was applied to, nor comparable situation to judge DCVax against. It was more of a hopeful story for everyone to hope for a miracle for him ... may M.H. RIP
In support of previous post, watch this interview on Naked Short selling and pay specific attention attention their TACTICS ...
I'll gladly offer a thought on this:
Time is Money.
With the amount of time invested, he/they (and i do suggest you consider the possibility of LC being a "they") is definitely profiting in some way from their time spent on their thousands of posts on this board.
Either LC "is" invested, or represents / works for someone who is (likely a major short).
Since I cannot see the current nonsense being posted by that account ... I would ask the forum a question of analysis:
Do the poats follow consistent logic? Or is there a bit of randomness to the thread of topics, ideas, etc. being posted?
If the latter, I suggest substantiated support to the idea that the LC account is a group of 2 or more people paid for their time on these boards by a major long term short, likely a HF or MM (looking at you, CDEL - I've seen your price movements and ladder drops on L2 way to often). If not even employees of the HF/MM themselves - as their time here would qualify in support of their working hours as well (we all know what they have up on their screens).
I'd be glad to submit an SEC tip off, but I think this board could offer a great initial analysis first.
What are your thoughts?
Just a thought - Does anyone think it is possible that LL's series of talks and presentations (and NEW Slides) is 100% strategically aligned together with NWBO / LP?
e.g. ... with the specific target of "prepping" the medical, scientific and academic communities on a new era of Statistical Analysis and external control arms, ahead of the eventual TLD / Publication that will be highly based on this? .....
She doesn't need to be discussing the actual trials to be prepping the "hearers" for what they are about to soon hear ..... (once TLD is published)
I wanna hope for PR / TLD after market close this evening at 4:01pm EST ... that would make my day .. and maybe life! And all of yours as well ... except the shorts, definitely not the shorts ....
Look at historical dates on OTCmarkets page ... seems they sometimes didn't file until even July.
I read those documents in full ... Reading helps.
No, it was already used in their last PR and 10-K filing
Can you provide more details? Otherwise, there is little credibility to this statement...
Tks
Short DCVAX Videos to Help Get the Word Out More:
https://vimeo.com/search?q=northwest%20biotherapeutics
HYPOTHESIS about "The Wall" at $1.50
CDEL has been pushing heavy volume (10-20x the Bid) each time we pass $1.49 ... i have a suspension here I've been thinking about for a while, based on a documentary I watched about Citadel and HFT (
So then, back to LP's comment's on that topic:
Question 3: Will NWBO unblind data prior to ASCO?
Answer (LP): "ASCO is certainly a great venue and it's been great for us when the timing has worked out, to be able to, as we did last year we had just announced the first interim data from our phase III trial, three days before ASCO, that just happened to work out beautifully on the timing. And a few years before that we had unveiled our initial DC Vax-Direct data. So we agree with you that it's great when that works. I can't answer your specific question about what is going to be the exact timing of unblinding. What I can tell you is what we said in our press release on November 19th, which was right after the SNO conference and right after that we had announced the updated data from the clinical trial. And we said, here are the steps we have to go through in order to get to unblinding and then what we would do with the unblinded data. And you can look at what those stages are and you can read what we said that each of those stages is a multi-month process. And so you can figure the arithmetic. The first stage, as we said, we have to get the Statistical Analysis Plan developed and then submit it to regulators, and approved by regulators. That doesn't sound like much but it is a ginormous exercise. We are working with teams of experts. Neurosurgeons, neuro-oncologists, radiologists, regulatory advisors, statisticians. All of these advisors in a big team, which is the right way to do it, and there's a lot of complexity, to say the least, about the statistical analysis plan and the statistics that you put in. There's no one way to do it. If you read all the literature, and there's no single cookie-cutter 'this is how you analyze a dataset from a phase III trial, bum, bum, bum.' There's a lot of decisions and choices to be made and stitched together into a coherent plan. You can perhaps understand from the description I just gave you, which I don't think rises to material by itself, description of what goes into the process, why we say that each stages is a multi-month process. Because you go through that process with two-dozen experts, and then you go through the process again in regulatory approval of that statistical analysis plan. And remember, we're in four separate countries with four separate regulators. Which, yes, it is more complex and takes longer, but also means we have multiple chances to win. So it's worth, and we believe very strongly it's worth the extra effort and expense and time and so forth. So I know it's really frustrating.
In parallel, and yes, people ask us all the time, 'are you at least doing things in parallel when you can?' Yes, we are. That thought has occurred to us. What we're doing in parallel is doing the final data collection. We had 82 sites in four countries with three languages. In order to do the final data collection a CRA Clinical Research Associate, employed by the independent CRO, the organization who is managing the trial independently, has to physically go to the sites, sit down with the trial database and the hospital records and compare them and find any piece of data that's missing or there's a discrepancy. The way the data gets captured in a clinical trial is in what's called a case report form. A case report form can be a hundred pages long. And you're looking for any piece of data that's either missing or there's a discrepancy. At every one of these 82 sites for every one of these 331 patients. And each one where there's a piece of data missing of there's a discrepancy, generates a query. And a query has to be resolved and the resolution has to be validated. The process can involve thousands of queries. That's just normal. That's what it takes to close out a dataset. And get to the point where we have a clean, full dataset that we can go to data-lock on.
So the big things that we are working toward and which we are doing in parallel, are moving toward the statistical analysis plan getting done and approved by regulators and moving towards data-lock. I hope that my description can help you see when we say it's a multi-month process, just making the physical visits at 82 sites and then resolving the thousands of queries you can understand why that's a multi-month process. So that's what we're in the middle of and we're as anxious as you are to see the results. That's the best I can tell you of the steps and the timeline."
ASCO Conf. Screenshot:
I normally would not share an email correspondence, but this seems simple enough without divulging personal information. But you should email them yourself just to know the information is as I presented. It's easy to do and you will know you are not relying on a 3rd party source. pic.twitter.com/osKjOgJYNc
— rj (@sharpie510) May 12, 2021
my thoughts are starting to go in this direction as well .... I know one thing, there is only 1 recommendation on LP's LinkedIn account, and it says EVERYTHING I need to know about her as a person and a leader .... and I trust her ... (I dont trust the markets, but I trust her) .... and she surely has something really great planned for all Stakeholders involved!
"Linda is a rare combination of brilliant intellect, tireless work ethic and wonderful human being. Her heart is as big as anyone I ve ever met. Anyone would be priviledged to work with her or for her. and an honor to be her friend ."
https://www.linkedin.com/in/lindapowers/
if you go to the Merck message boards, there is talk of them creating a new sales team .... but its top secret as to what they will be selling ....
Regarding ASCO: confirmation:
rj taking the covid-19 vaccine is a patriotic act @sharpie510·59m
I know there have been questions as to whether or not $NWBO will be at the ASCO 2021. I got confirmation from the A2Z Events Support Center (managing the virtual meeting) today that "Northwest Biotherapeutics is scheduled to exhibit at 2021 ASCO Annual Meeting".
I know there have been questions as to whether or not $NWBO will be at the ASCO 2021. I got confirmation from the A2Z Events Support Center (managing the virtual meeting) today that "Northwest Biotherapeutics is scheduled to exhibit at 2021 ASCO Annual Meeting".$mrk $bmy $rhhby
— rj (@sharpie510) May 12, 2021
I live in Switzerland - and its pretty obvious that is was sent via the UK PR team they just hired a couple months back. And they even misspelled Les Goldman's name and email ... its their first PR for NWBO
its simple - they hired a UK based PR firm ... remember?
Yep, it all in the 10k exactly like this ...
----
ITEM 1. BUSINESS.
Overview
...
On August 28, 2020, the Company acquired Flaskworks, LLC (“Flaskworks”), a company that has developed a system to close and automate the manufacturing of cell therapy products such as DCVax®. The Company acquired 100% of the ownership, and Flaskworks became a wholly-owned subsidiary of the Company. Flaskworks was previously owned by its technical founders and Corning Inc. The technical team from Flaskworks joined the Company as part of the Acquisition. It is anticipated that the Flaskworks system will enable substantial scale-up of production volumes of DCVax products and substantial reduction of production costs. The Company’s buildout of the Sawston, UK facility has been designed to proceed in phases, as modules, both for efficiency in the timing of capital costs and to allow flexibility in operations and usage. The Company anticipates that implementation of the Flaskworks system will enable certain phases of the buildout to be simplified and streamlined. For further details on the financial aspects of the acquisition, please see Item 8 Note 5 below.
-----
ITEM 1A. RISK FACTORS
...
The manufacturing of our product candidates will have to be greatly scaled up for commercialization, and neither we nor our contract manufacturers have experience with such scale-up.
As is the case with any clinical trial, our Phase III clinical trial of DCVax-L for GBM involves a number of patients that is a small fraction of the number of potential patients for whom DCVax-L may be applicable in the commercial market. The same will be true of our other clinical programs with DCVax-L or other DCVax product candidates. If our DCVax-L and/or other DCVax product candidates are approved for commercial sale, it will be necessary to greatly scale up the volume of manufacturing, far above the level needed for clinical trials. Neither we nor our contract manufacturers have experience with such scale-up. In addition, there are likely only a few consultants or advisors in the industry who have such experience and can provide guidance or assistance, because active immune therapies such as DCVax are a fundamentally new category of product in two major ways: these active immune therapy products consist of living cells, not chemical or biologic compounds, and the products are personalized. To our knowledge, very few such products have successfully completed the necessary scale-up for commercialization. For example, Dendreon Corporation encountered substantial difficulties trying to scale up the manufacturing of its Provenge® product for commercialization. To our knowledge, even the CAR-T products which are being commercialized have so far only scaled up to moderate product volumes.
...
The necessary specialized facilities, equipment and personnel may not be available or obtainable for the scale-up of manufacturing of our product candidates.
The manufacture of living cells requires specialized facilities, equipment and personnel which are entirely different than what is required for the manufacturing of chemical or biologic compounds. Scaling up the manufacturing of living cell products to volume levels required for commercialization will require enormous amounts of these specialized facilities, equipment and personnel - especially where, as in the case of our DCVax product candidates, the product is personalized and must be made for each patient individually. Since living cell products are so new, and have barely begun to reach commercialization, the supply of the specialized facilities and personnel needed for them is not widely available and therefore is in the process of being developed. However, there has been a sharp increase in the demand for these specialized facilities and personnel, as large numbers of companies seek to develop T cell and other immune cell products. It may not be possible for us or our manufacturers to obtain all of the specialized facilities and personnel needed for commercialization of our DCVax product candidates, or even for further sizeable trials. This could delay or halt our commercialization and/or further substantial trials.
We are anticipating that the production systems developed by Flaskworks may play an important role in enabling scale-up of production and reducing the number of GMP (clean room) suites and personnel needed for scale-up. However, the Flaskworks systems are still undergoing development and optimization, and have not been operated at commercial scale to date. It could turn out that the Flaskworks systems are not capable of or suitable for substantial scale-up, or not acceptable to regulatory authorities for such scale-up. It could also turn out that deployment the Flaskworks system does not reduce the number of GMP suites and personnel needed for DCVax production as anticipated.
And it was not QC'd very well ... they misspelled Les Goldman's name and his email address at the end ... they created a new company "@newbio.com"
According to investopedia, it seems the OTCBB was replaced by OTCQB and perhaps if someone at TD thinks something is still trading on an outdated / obsolete OTC board (BB), maybe that was the basis of their rejection(?).
"The OTCQB, also called "The Venture Market," is the middle tier of the over-the-counter (OTC) market for U.S. stocks. It was created in 2010 and consists mainly of early-stage and developing U.S. and international companies that are not yet able to qualify for the OTCQX but are not as speculative as the lowest-tier Pink Sheets.
The OTCQB replaced the Financial Industry Regulatory Authority (FINRA)-operated OTC Bulletin Board (OTCBB) as the main market for trading OTC securities that report to a U.S. regulator. As it has no minimum financial standards, the OTCQB often includes shell companies, penny stocks, and small foreign issuers."
https://www.investopedia.com/terms/o/otcqb.asp
Try telling him it's OTC/QB and not /BB .... but yeah, sucks to get such news. I hold all of my NWBO in TDA, but bought via TDA. Ridiculous that they won't accept them.
LOVE IT !!! <3
Can you elaborate on the "derisked" ? .... I'm sure many of us would love to hear the details spelled out
When you put it that way, I can see why AF says some of the things he says - about NWBO being a money machine for the Mgmt, taking money from our pockets to put into theirs ...
But I don't believe that is the situation - I believe in their intentions and that they are now there where they / we need to be ... and this final stretch does require patience, but it will be worth it for ALL Stakeholders involved ... from the families and patients, to the doctors, medical and science fields and for the patient investors who MADE IT ALL POSSIBLE !!!!!
Who cares about interim PPS? ... If you're not planning to sell anyway until after TLD, current price shouldn't matter ... cheaper it is, the more you can continue to load ... if you're a true Long. All this worry and talk about daily PPS is pretty irrelevant, UNLESS it breaks the technical trends that trigger algorithmic trading into a reversal towards buying with the Bulls and extending our breakout ... for now, were are trading within the expected PPS range in the long-term Pennant pattern:
See visualisation here:
$NWBO #NWBO #CuringGBM #CuringCancer #LindaLiau #NobelPrizeSoon pic.twitter.com/NB0TKdLcab
— CancerMoonshot (@yachtmastter) May 11, 2021
Linda Powers talked directly in her 2018 ASM discussions about "Institutional Investors" and their positions in NWBO ... I'd be careful to make assumptions on hearsay without facts ....
I love the last paragraph ..... =)
Short shout-out to say THANK YOU to everyone on this board.
Covid has been quite challenging in many ways, and at a minimum, the productive distraction of the engagement, humour, insight, etc from wonderful group that makes up this board has been very valuable to me ... and I just want to say THANK YOU to all of you, but especially to those of you with highly productive and insightful contributions. NWbio is surely proud to have you amoung their most long-term supporters, because without you many of us, and maybe even the company itself, probably wouldn't been here right now ....
THANK YOU
You can use http://wayback.archive.org to go back in time on a webpage, day by day, to see the changes that happened to it.
Yes, that is his obvious account, which hasn't even been used since 2016.
But I guess I meant to ask if we are aware of his burner account(s) pseudonyms? ... He likely has minions as well. I often wonder if LC and EX and the like are minions or one even the burner....
My bet is AF is behind one of the accounts ...